Fenebrutinib has the potential to become the first and only high-efficacy oral, brain-penetrant treatment for both RMS and PPMS, showing a profound benefit on relapsing and progressive disease biology
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
The new solution combines Watchmaker Genomics’ high-performance NGS chemistry with Volta’s digital fluidics platform
Investment marks continued progress against AbbVie's $100 billion commitment to U.S. R&D and capital investments, including manufacturing, over the next decade
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
HCG clinicians contributing to one of the largest bodies of oncology research from India
US revenue increased 43% to $12.9 billion, fueled by a 50% jump in volume, partially offset by a 7% decline in realized prices
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
After leading AstraZeneca's Oncology areas nationally and internationally, Laura Colón will assume the presidency of AstraZeneca in one of its priority global markets
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
